Evidence map›Paper›PMID 41439013›Full record

ArticleFrontiers in clinical diabetes and healthcare2025

MAFLD in Vietnam: a neglected public health challenge requiring urgent policy action.

Thong Duy Vo, Huong Tu Lam

Abstract read
In one paragraph

Article in Frontiers in clinical diabetes and healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thong Duy VoDepartment of Internal Medicine, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh, Vietnam.
Huong Tu LamDepartment of Internal Medicine, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh, Vietnam.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) is rapidly emerging as a major public health challenge in Vietnam, driven by rising rates of obesity, type 2 diabetes, and lifestyle changes. Although it contributes significantly to morbidity, mortality, and economic burden, MAFLD remains under-recognized within national health strategies and is largely neglected in non-communicable disease (NCD) frameworks. This narrative review synthesizes epidemiological, clinical, and health systems data on MAFLD in Vietnam, drawing on studies published between 2015 and 2024 alongside international guidelines to evaluate their relevance in the local healthcare setting. The evidence indicates that MAFLD affects more than one-quarter of urban adults and is steadily increasing in rural populations. Barriers to effective management include limited diagnostic capacity, lack of standardized guidelines, insufficient awareness among clinicians, and underdeveloped multidisciplinary care models. Complications are exacerbated by the coexistence of hepatitis B virus infection and the growing burden of cardiovascular comorbidities. Together, these factors heighten disease severity and accelerate progression to cirrhosis and hepatocellular carcinoma. Given these challenges, urgent multisectoral action is needed. We propose a strategic national roadmap that incorporates MAFLD into NCD policy, expands primary care screening using simple non-invasive tools, and invests in health workforce training to improve early detection and risk stratification. Strengthening multidisciplinary collaboration and leveraging digital health technologies can enhance patient engagement and access to care. Finally, regional cooperation and Vietnam's participation in international clinical trials are essential to accelerate innovation and policy response. In conclusion, MAFLD represents a neglected but pressing public health issue in Vietnam. Proactive and coordinated strategies are required to reduce its long-term health and socioeconomic impact and to position Vietnam as a regional leader in addressing metabolic liver disease.

Indexed as

epidemiologyfatty liverliver cirrhosisMAFLDmetabolic syndromenon-alcoholic fatty liver diseasepublic healthVietnam

Identifiers

PMID41439013
PMCPMC12719252

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.